

## **orBec<sup>®</sup> (oral beclomethasone 17,21-dipropionate) – Key References**

Adams NP, Bestall JB, Malouf R et al. Inhaled beclomethasone versus placebo for chronic asthma. Cochrane Review. In: The Cochrane Library. 2005;1. Chichester, UK: John Wiley & Sons, Ltd.

Andersson P, Ryrfeldt A. Biotransformation of the topical glucocorticoids budesonide and beclomethasone 17 alpha,21 dipropionate in human liver and lung homogenate. *J Pharm Pharmacol* 1984;36:763-765.

Baehr PH, Levine DS, Bouvier ME et al. Oral beclomethasone dipropionate for treatment of human intestinal graft-versus-host disease. *Transplantation*. 1995;60:1231-1238.

Barnes NC. The properties of inhaled corticosteroids: similarities and differences. *Prim Care Respir J*. 2007;16:149-154.

Brogden RN, Pinder RM, Sawyer PR et al. Beclomethasone dipropionate inhaler: A review of its pharmacology, therapeutic value and adverse effects I: Asthma. *Drugs*. 1975a;10:166-210.

Brogden RN, Pinder RM, Sawyer PR et al. Beclomethasone dipropionate: II: Allergic rhinitis and other conditions. *Drugs*. 1975b;10:211-217.

Brogden RN, Heel RC, Speight TM et al. Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis. *Drugs*. 1984;29: 99-126.

Burggraaf J, van Haarst AD, Fockens P et al. The gastrointestinal passage and release of beclomethasone dipropionate from oral delivery systems in ileostomy volunteers. *Br J Clin Pharmacol*. 1998;46: 207-214.

Buttgereit F, Burmester G-R, Lipworth BJ. Optimised glucocorticoid therapy: the sharpening of an old spear. *Lancet*. 2005;365:801-803.

Campieri M, Cottone M, Miglio F et al. Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis. *Aliment Pharmacol Ther*. 1998;12: 361-366.

Daley-Yates PT, Price AC, Sisson JR et al. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. *Br J of Clin Pharmacol*. 2001;51:400-409.

Elkon KB, Siier R, Saftel HC. Immunological studies of eosinophilic gastro-interitis and treatment with disodium cromoglycate and beclomethasone dipropionate. *S Afr Med J*. 1977;52:838-841.

Filipovich AH, Weisdorf D, Pavletic S et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I.

Diagnosis and Staging Working Group Report. *Biol Blood Marrow Transplant*. 2005;11:945-955.

Díez-Campelo M, Sánchez-Guijo FM, Pérez Simón JA. Beclometasone dipropionate: a topically active corticosteroid for the treatment of gastrointestinal graft-versus-host disease. *Expert Opin Investig Drugs*. 2008;17(9); 1389-1401.

Fukuda T, Boeckh M, Carter RA et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. *Blood*. 2003;102:827-833.

Hakki M, Riddell SR, Storek J et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. *Blood*. 2003;102:3060-3067.

Harris DM. Some properties of beclomethasone dipropionate and related steroids in man. *Postgrad Med J*. 1975;51:20-25.

Hockenbery DM, Cruickshank S, Rodell TC et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. *Blood*. 2007;109:4557-4563

Issar M, Sahasranaman S, Buchwald P et al. Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. *Eur Respir J*. 2006;27:511-516.

Iyer RV, Hahn T, Roy HN et al. Long-term use of oral beclomethasone dipropionate for the treatment of gastrointestinal graft-versus-host disease. *Biol Blood Marrow Transplant*. 2005;11:587-592.

Johansson SA, Andersson KE, Brattsand R et al. Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man. *Eur J Respir Dis Suppl*. 1982;22:523-529.

Kumana CR, Seaton T, Meghji M et al. Beclomethasone dipropionate enemas for treating inflammatory bowel disease without producing Cushing's syndrome or hypothalamic pituitary adrenal suppression. *Lancet*. 1982;1:579-583.

Levine DS, Rubin CE. Topical beclomethasone dipropionate enemas improve distal ulcerative colitis and idiopathic proctitis without systemic toxicity. *Gastroenterology*. 1985;88:1473.

Levine DS, Raisys VA, Ainardi V. Coating of oral beclomethasone dipropionate capsules with cellulose acetate phthalate enhances delivery of topically active anti-inflammatory drug to the terminal ileum. *Gastroenterology*. 1987;92:1037-1044.

Levine, DS. Immune modulating therapies for idiopathic inflammatory bowel disease. *Adv Pharmacol*. 1994;25:171-234.

Lipworth BJ. Systemic adverse events of inhaled corticosteroids. *Arch Int Med.* 1999;159:941-955.

Lofberg R, Ostergaard Thomsen O, Langholz E et al. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. *Aliment Pharmacol Ther.* 1994;8:623-629.

Lofberg R, Rutgeerts P, Malchow H et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. *Gut.* 1996;39:82-86.

Marr KA, Carter RA, Boeckh M et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. *Blood.* 2002;100:4358-4366.

Martin LE, Tanner RJN, Clark TJH et al. Absorption and metabolism of orally administered beclomethasone dipropionate. *Clin Pharmacol Ther.* 1974;15:267-275.

Martin LE, Harrison C, Tanner RJN. Metabolism of beclomethasone dipropionate by animals and man. *Postgrad Med J.* 1975;51:11-20.

McDonald GB. Oral beclomethasone dipropionate: a topically active corticosteroid for the treatment of gastrointestinal graft-versus-host disease following allogeneic hematopoietic cell transplantation. *Expert Opin Investig Drugs.* 2007;16(10):1-16.

McDonald GB, Bouvier M, Hockenbery DM et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. *Gastroenterology.* 1998;115:28-35.

Mulder CJ, Endert E, van der HH et al. Comparison of beclomethasone dipropionate (2 and 3 mg) and prednisolone sodium phosphate enemas (30 mg) in the treatment of ulcerative proctitis. An adrenocortical approach. *Neth J Med.* 1989;35:18-24.

Nichols WG, Corey L, Gooley T et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. *Blood.* 2001;97:867-874.

Oishi T, Deguchi T, Marumo H. Metabolism of beclomethasone 17,21-dipropionate. *Appl Pharmacol.* 1981;22:717-727.

Rizello F, Gionchetti P, D'Arienzo A et al. Oral beclomethasone dipropionate in the treatment of active ulcerative colitis: a double blind placebo controlled study. *Aliment Pharmacol Ther.* 2002;16:1109-1116.

Rutgeerts P, Lofberg R, Malchow H et al. A comparison of budesonide with prednisolone for active Crohn's disease. *N Engl J Med.* 1994;331:842-845.

Steed KP, Hooper G, Ventura P et al. The in vivo behaviour of a colonic delivery system: A pilot study in man. *Int J Pharm.* 1994;112:199-206.

van der Heide H, van den Brandt-Gradel V, Tytgat GNJ et al. Comparison of beclomethasone dipropionate and prednisolone 21-phosphate enemas in the treatment of ulcerative proctitis. *J Clin Gastroenterol.* 1988;10:169-172.

Villanueva FN, Perez-Simon JA, Silva FF et al. Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Chronic Graft-versus-Host Disease. *Biol Blood Marrow Transplant.* 2009;15:1331-1336.